Evidence map›Paper›PMID 12702614›Full record

SynthesisBMJ (Clinical research ed.)2003

Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review.

Peter Herbison, Jean Hay-Smith, Gaye Ellis, Kate Moore

Open access · bronzeAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMJ (Clinical research ed.), 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 3 pooled it
29.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 3 syntheses or guidelines pooled it, 335 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Botulinum toxin-A for idiopathic overactivity of the vesical detrusor: a 2-year follow-up.International urogynecology journal and pelvic floor dysfunction · 2008
    Trial
  9. Trial
  10. Rehabilitation versus drug therapy for urge urinary incontinence: long-term outcomes.International urogynecology journal and pelvic floor dysfunction · 2008
    Trial
  11. Trial
  12. Impact of duloxetine on quality of life for women with symptoms of urinary incontinence.International urogynecology journal and pelvic floor dysfunction
    Trial
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Peter HerbisonDepartment of Preventive and Social Medicine, University of Otago, PO Box 913, Dunedin, New Zealand. peter.herbison@otago.ac.nz
Jean Hay-Smith
Gaye Ellis
Kate Moore
University of Otago · NZSt George Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo determine the effectiveness of anticholinergic drugs for the treatment of overactive bladder syndrome.

designSystematic review of randomised controlled trials. DATA SOURCES: Published papers and abstracts. STUDY SELECTION: Randomised controlled trials with anticholinergic drug treatment in one arm and placebo in another. DATA EXTRACTION: Primary outcomes of interest were patient perceived cure or improvement in symptoms, differences in number of incontinent episodes and number of voids in 24 hours, and side effects. Secondary outcomes of interest were urodynamic measures of bladder function (volume at first contraction, maximum cystometric capacity, and residual volume) and adverse events. DATA SYNTHESIS: 32 trials were included, totalling 6800 participants. Most trials were described as double blind but were variable in other aspects of quality. At the end of treatment, cure or improvement (relative risk 1.41, 95% confidence interval 1.29 to 1.54), differences in incontinent episodes in 24 hours (estimated mean difference 0.6, 0.4 to 0.8), number of voids in 24 hours (0.6, 0.4 to 0.8), maximum cystometric capacity (54 ml, 43 ml to 66 ml), and volume at first contraction (52 ml, 37 ml to 67 ml), were significantly in favour of anticholinergics (P<0.0001 for all). Anticholinergics were associated with significantly higher residual volumes (4 ml, 1 ml to 7 ml; P=0.02) and an increased rate of dry mouth (relative risk 2.56, 2.24 to 2.92; P<0.0001). Sensitivity analysis, although affected by small numbers of studies, showed little likelihood of an effect of age, sex, diagnosis, or choice of drug.

conclusionsAlthough statistically significant, the differences between anticholinergic drugs and placebo were small, apart from the increased rate of dry mouth in patients receiving active treatment. For many of the outcomes studied, the observed difference between anticholinergics and placebo may be of questionable clinical significance. None of these studies provided data on long term outcome.

Indexed as

Cholinergic AntagonistsFemaleHumansMaleRandomized Controlled Trials as TopicTreatment OutcomeUrinary Bladder DiseasesUrinary RetentionCholinergic Antagonists

Identifiers

PMID12702614
PMCPMC153465
OpenAlexW2119809361

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.